EPS: As of FY2025 Q1, the actual value is USD 0.07.

Segment Revenue

• The company has not generated any operating revenues as of March 31, 2025, and will not do so until after the completion of an initial Business Combination.

Operational Metrics

• Net income for the three months ended March 31, 2025, was $1,020,970, primarily due to interest earned on cash held in the Trust Account amounting to $1,234,208, offset by operational costs of $213,238.
• For the period from February 5, 2024 (inception) through March 31, 2024, the company incurred a net loss of $60,420 due to formation and operating costs.

Cash Flow

• Cash used in operating activities for the three months ended March 31, 2025, was - $146,448.
• As of March 31, 2025, cash held in the Trust Account was $120,328,139.

Unique Metrics

• The company has placed an aggregate of $115,575,000 ($10.05 per Unit) in the Trust Account following the Initial Public Offering and private placement.

Future Outlook and Strategy

• Core Business Focus: The company intends to pursue a Business Combination with a target in the deep technology sector, including artificial intelligence, quantum computing, and biotechnology, focusing on businesses in Asia.
• Non-Core Business: The company will not consummate a Business Combination with an entity or business with China operations consolidated through a variable interest entity (VIE) structure.
• Priority: The company has 18 months from the closing of the Initial Public Offering to consummate a Business Combination, failing which it will proceed to commence voluntary liquidation.